Infliximab; 3. Follow-up study; Presenting Author: MAJUN FANG Additional Authors: KONG CHAO-MEIKONG CHAO-MEI KONG CHAO-MEI, ZHANGYU SHU, ZHANGZHEN YU Corresponding Author: KONG CHAO-MEIKONG CHAO-MEI KONG CHAO-MEI Affiliations: Nanjing Medical University Objective: To observe the expression of Corticotrophin Releasing Factor Receptor 2 (CRFR2) in Ulcerative Colitis (UC) and the relationship between CRFR2 and ICAM-1, NF-κB P65, IL-6, and to study the role of CRFR2 in UC pathogenesis. Methods: CRFR2, ICAM-1 and NF-κB P65 in colonic mucosal biopsy samples collected from 30 patients with active UC, 30 patients with remittent UC and 30 healthy people were studied by immunohistochemistry.
IL-6 in serum KU-57788 supplier was studied by ELISA. Results: Colon
tissues from patients with UC had significant increases in expression to CRFR2 compared with the remittent group and the control group (all P < 0.05), but there was remarkable statistical significance between the remittent group and the control group (P > 0.05). There was significant correlation between CRFR2 and ICAM-1, NF-κB P65, IL-6.(all P < 0.05). Conclusion: significantly increased in active UC patients, compared with the remittent group and a control group, our results and the present study showed that CRFR2 may act as a possible local pro-inflammatory mediator in UC. Key Word(s): 1. CRFR2; 2. Ulcerative Colitis; 3. NF-κB P65; 4. IL-6; Presenting Author: NAIZHONG HU Additional Authors: ZHONGJU YANG Corresponding Author: NAIZHONG HU Affiliations: he First Affiliated Hospital NVP-LDE225 ic50 of Anhui Medical University; the Third Affiliated Hospital of Anhui Medical University Objective: To O-methylated flavonoid analyze the clinical efficacy, safety and appropriate dose of azathioprine in treatment of chronic corticosteroid-dependent ulcerative colitis. Methods: Selected the hospitalized patients and outpatients of chronic corticosteroid-dependent ulcerative colitis (UC), who continued to use azathioprine (AZA) for more than 6 months and had a regular follow-up, at the department of gastroenterology, the first
affiliated hospital of Anhui Medical University from 2000 to 2011. Observed and contrasted the clinical manifestations of stool frequency, hematochezia, colonoscopy, laboratory indicators of CRP, ESR, blood routine, liver and kidney function with AZA of different doses before and after treatment. Used unified standard to evaluate clinical efficacy of AZA, recorded adverse reactions, and analysed therapeutic effect, safety and proper dose of AZA in management of chronic refractory UC. Results: Collected 30 cases of patients with chronic refractory UC, eliminated 3 cases of irregular or initialized taking AZA, 3 cases of stopping AZA with a reduced white blood cells in 6 months, and finally included 24 cases of chronic corticosteroid-dependent UC which met the inclusion criteria. There were 18 cases (75%) of males and 8 cases (25%) of females.